Latest news with #RonanKelly
Business Wire
3 days ago
- Health
- Business Wire
Onc.AI to Present Breakthrough Deep Learning Radiomic Biomarker Results at 2025 ASCO Annual Meeting
CHICAGO--(BUSINESS WIRE)-- a digital health company developing AI-powered oncology clinical management solutions, today announced that new validation study results from research collaborations with Pfizer, Baylor Scott & White and the University of Rochester Medical Center will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30–June 3, 2025, in Chicago, IL. Deep learning radiomics to transform oncology clinical development and improve upon RECIST 1.1 (#better_recist) Share poster presentation showcases its FDA-breakthrough designated deep learning radiomics model, Serial CTRS, which evaluates changes across routine CT scans over time to predict overall survival in late-stage non–small cell lung cancer (NSCLC) and other solid tumor types. In collaboration with Baylor Scott & White and Pfizer, Serial CTRS has demonstrated: Superior prediction of overall survival (OS): Hazard ratios (HRs) for OS improvement and stratification exceed those of the conventional imaging approach (RECIST 1.1). Generalizability across real-world and clinical trial cohorts: Robust performance in both routine real-world datasets and a Pfizer-sponsored PD-1 checkpoint inhibitor trial. Actionable insights for early treatment adaptation: Dynamic monitoring identifies non-responders months before conventional criteria would signal poor prognosis. At the ASCO Innovation Hub (IH13), will share latest results from its pipeline of deep learning radiomic models to customers and partners spanning medical oncologist investigators and biopharma companies looking to accelerate oncology clinical development. Program Highlights Poster Presentation: Abstract #253138: Validation of Serial CTRS for Early Immunotherapy Response Prediction in Metastatic NSCLC – Presenter: Ronan Kelly, MD, Baylor Scott & White Date & Time: June 1, 2025; 9:00 am–12:00 pm CDT Location: Hall A, Poster Board 325 Abstract #251996: Retrospective Single-Institution Application of a Deep Learning–Based Radiomic Score in Metastatic NSCLC: Potential Impact on First-Line Treatment Decisions – Lead Author: Nicholas Love, MD, University of Rochester Abstract #245837: Image Harmonization for PD-(L)1 Immune Checkpoint Inhibitor Response Prediction Using Deep Learning Radiomic Features in Advanced NSCLC – Lead Author: Taly Gilat-Schmidt, PhD, 'These strong validation study results spanned both RWD and a pharma-sponsored clinical trial. Serial CTRS could represent a high-potential tool for medical oncologists and for optimizing pharma clinical development,' said Dr. Ronan Kelly, MD, Director of Oncology at the Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas Texas 'Our retrospective study highlights how Deep Learning Radiomic baseline score can be extremely helpful to medical oncologists as a prognostic marker for first line mutation negative NSCLC patients,' added Arpan Patel, MD and Associate Professor of Medical Oncology at the University of Rochester Medical Center. About is a digital health company developing AI-driven oncology clinical management solutions using advanced Deep Learning applied to routine diagnostic images. The company's platform is applied at the point of care by medical oncologists and is also leveraged by global pharmaceutical leaders to accelerate oncology drug development. is backed by premier institutional investors, including Blue Venture Fund, Action Potential Venture Capital (GSK) and MassMutual Alternative Investments. is also supported by the National Cancer Institute SBIR program (1R44CA291456-01A1). For more information, please visit:
Yahoo
24-04-2025
- Business
- Yahoo
Herbal Oasis Wins National Recognition at the 2025 High Spirits Awards
Charlotte, North Carolina--(Newsfile Corp. - April 24, 2025) - Herbal Oasis, a rising star in the alternative hemp beverage space, has earned national acclaim with a Gold Medal for Mango Bliss, Silver Medal for both Lemon Lift and Tropical Twist and a Bronze Medal for Berry Fusion at the 2025 High Spirits Awards, a leading showcase of excellence in cannabinoid-infused drinks hosted by the L.A. Spirits Awards in California. To view an enhanced version of this graphic, please visit: Herbal Oasis Social Tonic was awarded in the "Other Infused Beverage Products" category, a distinction that highlights unique formats pushing the edge of THC beverage innovation. The recognition comes just four months after the brand's national launch, marking a fast ascent for a beverage positioned as a stylish, non-alcoholic alternative for social settings. "We created Herbal Oasis for people looking for a better way to connect-as an alternative to alcohol," said Ronan Kelly, CEO of cbdM. "Winning this award validates what our community has been telling us: it tastes great, it feels great, and it fits the vibe." Launched at the end of 2024, Herbal Oasis was inspired by the growing movement toward low-dose, social THC consumption, especially among health-conscious adults looking for alternatives to traditional cocktails or beer. Hemp-derived THC beverages are one of the fastest growing consumer beverage categories. Euromonitor International estimates sales of hemp-derived THC beverages more than doubled in 2024 and are projected to balloon to $4.1 billion by 2028. Each can of Oasis combines hemp-derived THC, CBG, and functional mushrooms to create a vibrant, elevated experience-without regret. Oasis began hitting shelves in Alabama, Florida, and North Carolina in late March, with additional locations launching throughout spring and summer. Oasis is also available for nationwide delivery from The High Spirits Awards, founded by the creators of the L.A. Spirits Awards, evaluates products across 11 infused beverage categories. Winners are selected by a panel of experienced beverage professionals based on flavor, balance, packaging, and overall drinking experience. Medal designations range from Platinum to Bronze, with Best-in-Show honors reserved for the top of each category. About Herbal Oasis Herbal Oasis is a premium THC-infused social seltzer that blends cannabinoids and nootropic mushrooms to deliver a fast-acting, functional beverage made for presence and connection. With an alcohol-free formula and wellness-forward ingredients, Oasis invites a better way to drink-one rooted in clarity, balance, and joy. More information can be found at Oasis is a subsidiary of cbdMD, Inc. To learn more or find a retailer near you, visit: About cbdMD, Inc. cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products, and our ATRx brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD oil and Full Spectrum products as well as our other brands, please visit or follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products. Forward-Looking Statements This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on our ability to continue as a going concern, increasing our revenues, the development or future sales of Oasis products, regaining compliance with NYSE American continued listing requirements and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 as filed with the Securities and Exchange Commission (the "SEC") on December 17, 2024, and our other filings with the SEC. All forward-looking statements, including Euromonitor international projections, involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release. 1 THC-free is defined as below the level of detection using validated scientific analytical methods. Contact Information: cbdMD, KennedyChief Executive Officer and Chief Financial OfficerIR@ 445-3064 Media Contact: Madison Fero, cbdMD, 980-240-5727, To view the source version of this press release, please visit Sign in to access your portfolio
